Outset Medical, Inc. (NASDAQ:OM) CEO Sells $26,913.87 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 33,227 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $0.81, for a total value of $26,913.87. Following the completion of the sale, the chief executive officer now directly owns 861,397 shares of the company’s stock, valued at $697,731.57. This represents a 3.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Leslie Trigg also recently made the following trade(s):

• On Tuesday, January 7th, Leslie Trigg sold 10,227 shares of Outset Medical stock. The shares were sold at an average price of $1.29, for a total transaction of $13,192.83.
• On Friday, November 15th, Leslie Trigg sold 5,645 shares of Outset Medical stock. The stock was sold at an average price of $0.80, for a total transaction of $4,516.00.

Outset Medical Trading Down 6.1 %

Shares of Outset Medical stock opened at $0.76 on Thursday. The company’s fifty day moving average price is $1.01 and its two-hundred day moving average price is $1.39. The firm has a market capitalization of $40.06 million, a PE ratio of -0.28 and a beta of 2.05. Outset Medical, Inc. has a 52-week low of $0.44 and a 52-week high of $5.22. The company has a debt-to-equity ratio of 4.12, a current ratio of 6.49 and a quick ratio of 5.04.

Institutional Trading of Outset Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA boosted its stake in Outset Medical by 118.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 1,538,859 shares of the company’s stock valued at $5,925,000 after buying an additional 834,663 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Outset Medical in the 2nd quarter valued at $49,000. Marshall Wace LLP grew its holdings in shares of Outset Medical by 487.8% in the 2nd quarter. Marshall Wace LLP now owns 314,187 shares of the company’s stock worth $1,210,000 after purchasing an additional 260,740 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Outset Medical by 228.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 200,939 shares of the company’s stock worth $774,000 after purchasing an additional 139,740 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its holdings in Outset Medical by 74.1% during the 2nd quarter. Squarepoint Ops LLC now owns 80,300 shares of the company’s stock valued at $309,000 after purchasing an additional 34,187 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada restated a “sector perform” rating and set a $3.00 price target on shares of Outset Medical in a research note on Tuesday, January 7th.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.